Een in de klinische praktijk uitgevoerde studie evalueerde de effectiviteit en veiligheid van pyrotinib bij patiënten met lapatinib - Tykerb resistente HER2-positieve uitgezaaide borstkanker. Uit de resultaten blijkt dat bij deze groep van patiénten de behandeling met pyrotinib alsnog bij een aantal patiënten aansloeg en zorgde voor een langere progressievrije tijd dan alleen met lapatinib.
Hier een paar grafieken uit de studie. Daaronder het abstract en ook studies bij andere vormen van kanker:
In deze grafiek hoe patiënten reageerden op de behandeling met pyrotinib.
Summary of pyrotinib-based therapy response in lapatinib-resistant HER2-positive metastatic breast cancer patients.
Klik op de titel van het abstract voor het volledige studierapport:
Background: Tyrosine kinase inhibitors (TKIs) are effective for treating human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer. However, therapies subsequent to TKI progression remain controversial, and effective treatments for TKI resistance are urgently needed. We evaluate the practice of exchange of TKIs, which involves treatment with a different TKI following prior TKI failure. Specifically, this study investigated the efficacy of pyrotinib-based therapy in lapatinib-resistant HER2-positive metastatic breast cancer (NCT04899128).
Methods: This real-world study included 76 patients diagnosed with HER2-positive metastatic breast cancer who received pyrotinib-based therapy after lapatinib progression at four Chinese institutions between August 2018 and March 2020. Progression-free survival (PFS), overall survival (OS), objective response rate (ORR), clinical benefit rate (CBR), and toxicity profiles were reported.
Results: All patients received pyrotinib-based therapy in two or later line therapy. The median PFS was 8.0 months (95% CI 5.1-10.9). OS has not reached. The ORR and CBR were 17.1% and 60.5%, respectively. The median PFS was 7.1 months (95% CI 5.633-8.567) and intracranial ORR was 42.9% in patients who had brain metastasis (n = 14). Patients who benefited from lapatinib ⩾ 6.0 months prior exhibited a longer PFS (10.6 versus 6.0 months, p = 0.034, stratified hazard ratio (HR) 0.534, 95% CI 0.293-0.975). The most common adverse effects were diarrhea (n = 34, 44.7%) and hand-foot syndrome (n = 10, 13.2%).
Conclusion: Pyrotinib-based therapy has the potential to improve survival in patients with lapatinib-resistant HER2-positive metastatic breast cancer, including those with brain metastases. Pyrotinib could provide a clinically significant increase in PFS for patients who benefited from prior lapatinib.
Keywords: breast cancer; human epidermal growth factor receptor 2; lapatinib; metastasis; pyrotinib.
© The Author(s), 2022.
Conflict of interest statement
Conflict of interest statement: The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
The Efficacy of Pyrotinib as a Third- or Higher-Line Treatment in HER2-Positive Metastatic Breast Cancer Patients Exposed to Lapatinib Compared to Lapatinib-Naive Patients: A Real-World Study
- 1Department of General Surgery, The Second Xiangya Hospital, Central South University, Changsha, China
- 2Department of General Surgery, Xiangya Hospital, Central South University, Changsha, China
- 3Department of Internal Medicine of Breast, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China
- 4Department of Breast and Thyroid Surgery, Hunan Provincial People’s Hospital, Changsha, China
- 5Department of Breast and Thyroid Surgery, Third Xiangya Hospital, Central South University, Changsha, China
- 6Department of Breast Surgery, Xiangya Hospital, Central South University, Changsha, China
- 7Department of Oncology, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China
- 8Department of Oncology, The Second Xiangya Hospital, Central South University, Changsha, China
- 9Department of Traditional Chinese Medicine, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China
- 10Department of Internal Medicine–Oncology, Xiangya Hospital, Central South University, Changsha, China
Background: Pyrotinib is a novel irreversible pan-ErbB receptor tyrosine kinase inhibitor. Evidence of the efficacy of pyrotinib-based treatments for HER2-positive metastatic breast cancer (MBC) in patients exposed to lapatinib is limited.
Methods: Ninety-four patients who received pyrotinib as a third- or higher-line treatment for HER2-positive MBC were included in this retrospective study. The primary and secondary endpoints were overall survival (OS) and progression‐free survival (PFS). Propensity score matching (PSM) and inverse probability of treatment weighting (IPTW) analysis were implemented to balance important patient characteristics between groups.
Results: Thirty (31.9%) patients were pretreated with lapatinib and subsequently received pyrotinib as an anti-HER2 treatment, and 64 (68.1%) patients did not receive this treatment. The OS and PFS indicated a beneficial trend in lapatinib-naive group compared to lapatinib-treated group in either the original cohort (PFS: 9.02 vs 6.36 months, p = 0.05; OS: 20.73 vs 14.35 months, p = 0.08) or the PSM (PFS: 9.02 vs 6.08 months, p = 0.07; OS: 19.07 vs 18.00 months, p = 0.61) or IPTW (PFS: 9.90 vs 6.17 months, p = 0.05; OS: 19.53 vs 15.10 months, p = 0.08) cohorts. Subgroup analyses demonstrated lapatinib treatment-related differences in PFS in the premenopausal subgroup and the no prior trastuzumab treatment subgroup, but no significant differences were observed in OS.
Conclusion: Pyrotinib-based therapy demonstrated promising effects in HER2-positive MBC patients in a real-world study, especially in lapatinib-naive patients, and also some activity in lapatinib-treated patients.
Phase I Study and Biomarker Analysis of Pyrotinib, a Novel Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer.J Clin Oncol. 2017 Sep 20;35(27):3105-3112. doi: 10.1200/JCO.2016.69.6179. Epub 2017 May 12.PMID: 28498781 Clinical Trial.
Pyrotinib in the treatment of human epidermal growth factor receptor 2-positive metastatic breast cancer: A case report.Medicine (Baltimore). 2020 Jun 19;99(25):e20809. doi: 10.1097/MD.0000000000020809.PMID: 32569228 Free PMC article.
Pyrotinib combined with thalidomide in advanced non-small-cell lung cancer patients harboring HER2 exon 20 insertions (PRIDE): protocol of an open-label, single-arm phase II trial.BMC Cancer. 2021 Sep 16;21(1):1033. doi: 10.1186/s12885-021-08759-8.PMID: 34530760 Free PMC article. Clinical Trial.
Real-World Data of Pyrotinib-Based Therapy in Metastatic HER2-Positive Breast Cancer: Promising Efficacy in Lapatinib-Treated Patients and in Brain Metastasis.Cancer Res Treat. 2020 Oct;52(4):1059-1066. doi: 10.4143/crt.2019.633. Epub 2020 Apr 24.PMID: 32340083 Free PMC article.
Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases.Clin Ther. 2008 Aug;30(8):1426-47. doi: 10.1016/j.clinthera.2008.08.008.PMID: 18803986 Review.
Cited by 41 articles
Twenty-eight months progression-free survival after pyrotinib therapy for HER2-positive recurrent ovarian clear cell carcinoma: a case report.Ann Transl Med. 2022 Mar;10(6):387. doi: 10.21037/atm-22-1045.PMID: 35433993 Free PMC article.
Neoadjuvant pyrotinib plus trastuzumab and nab-paclitaxel for HER2-positive early or locally advanced breast cancer: an exploratory phase II trial.Gland Surg. 2022 Jan;11(1):216-225. doi: 10.21037/gs-21-911.PMID: 35242683 Free PMC article.
New and Emerging Targeted Therapies for Advanced Breast Cancer.Int J Mol Sci. 2022 Feb 18;23(4):2288. doi: 10.3390/ijms23042288.PMID: 35216405 Free PMC article. Review.
Anti-HER2 therapy in metastatic breast cancer: many choices and future directions.Cancer Metastasis Rev. 2022 Mar;41(1):193-209. doi: 10.1007/s10555-022-10021-x. Epub 2022 Feb 10.PMID: 35142964 Free PMC article. Review.
Efficacy and safety of pyrotinib in advanced lung adenocarcinoma with HER2 mutations: a multicenter, single-arm, phase II trial.BMC Med. 2022 Feb 1;20(1):42. doi: 10.1186/s12916-022-02245-z.PMID: 35101045 Free PMC article. Clinical Trial.